Navigation Links
FDA Panel Gives Blessing to New Weight-Loss Drug
Date:5/12/2012

THURSDAY, May 10 (HealthDay News) -- An advisory panel to the U.S. Food and Drug Administration on Thursday recommended approval of the weight-loss medication lorcaserin, even though concerns remain about cardiovascular side effects.

If the agency were to give the nod to the drug, lorcaserin would become the first new weight-loss pill made available to Americans in a decade. The FDA is not bound to follow the advice of its expert panels, but it typically does.

The panel of experts voted 18 to 4, with one abstention, for approval, saying the drug's benefits "outweigh the potential risks when used long term" for people battling excess weight, the Associated Press reported.

Lorcaserin has not always received such a favorable reception. According to the AP, in 2010 scientists voiced concern that the drug might come with health risks, citing tumors that had developed in animal testing involving the drug.

However, Arena Pharmaceuticals, the San Francisco-based company that makes lorcaserin, has since submitted additional data in hopes the FDA might look more favorably on the drug.

According to a review of the available research posted by FDA staff online on Tuesday, that new data suggests that lorcaserin carries only a "negligible risk" of cancer in humans, the AP said. But concerns over the potential for cardiovascular risks -- hypertension in people with diabetes, for example, or injury to heart valves -- remain.

According to the AP, lorcaserin is one of three experimental weight-loss drugs that the FDA is taking a second look at after first saying no to the medications in 2010 or early 2011 because of concerns about significant side effects.

In February, another new weight-loss drug, Qnexa, was endorsed by an FDA advisory panel. The agency is expected to make a final decision on Qnexa in July.

More information

Find out more about healthy weight loss at the U.S. Centers for Disease Control and Prevention.

-- E.J. Mundell

SOURCE: Associated Press


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. U.S. Panel Rejects Ovarian Cancer Screening
2. Panel of serum biomarkers may reduce number of lung biopsies needed
3. FDA Panel Cites Clot Risk From Contraceptive Patch
4. Panel endorses active monitoring and delay of treatment for low-risk prostate cancer
5. Expert Panel Pinpoints Environmental Culprits in Breast Cancer
6. FDA Panels to Weigh Safety of Newer Forms of the Pill
7. Panel of melanoma mutations opens door to new treatment possibilities
8. Many on Medical Guideline Panels Have Conflicts of Interest: Study
9. Panels Rejection of PSA Test Spurs Mixed Reaction From Experts
10. Osteoporosis Drugs Safety Subject of FDA Panel
11. U.S. Panel Recommends Free Coverage of Birth Control
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Gives Blessing to New Weight-Loss Drug 
(Date:2/5/2016)... NY & Salt Lake City, UT (PRWEB) , ... February 05, ... ... Founder of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author ... the New Really Cool Humans Amateur TV Network. , Each week, on his weekly ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held ... Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research ... Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative event ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... addition of micro-needling services in their Napa Valley office. The technique utilizes the ... Surgery Associates, Dr. Canales and Dr. Furnas, are part of only a select ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... H. Van Allen have signed a joint enrollment and degree completion agreement. ... toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows students ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... exclusively to funding innovative lymphoma research and serving the lymphoma community through a ... to once again host, Swirl, A Wine Tasting Event at the La Gorce ...
Breaking Medicine News(10 mins):
(Date:2/4/2016)... , Feb. 4, 2016 Summary Breast ... cancer and the most common cancer in women worldwide, ... disease exceedingly prevalent. The number of women diagnosed with ... but the number of deaths has declined due to ... treatment has been revolutionized in the past four decades, ...
(Date:2/4/2016)... Feb. 4, 2016 Mettler-Toledo International Inc. (NYSE: ... 2015.  Provided below are the highlights: , ... compared with the prior year.  Reported sales decreased 3% ... quarter. , Net earnings per diluted share as ... prior- year period.  Adjusted EPS was $4.65, an increase ...
(Date:2/4/2016)... 2016  Blueprint Medicines Corporation (NASDAQ: BPMC ... selective investigational kinase medicines for patients with genomically ... board of directors of Lonnel Coats , ... of industry-related experience. Jeffrey Albers ... strong strategic experience developing and commercializing numerous oncology ...
Breaking Medicine Technology: